Refine by
Clinical Development Services In Israel
7 services found
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Pluristem’s goal is to provide patients, physicians and healthcare systems around the globe with standardized, easy to use and highly effective PLX cell products that need no genetic or tissue matching prior to administration. We are active with many respectful regulatory agencies worldwide to advance our clinical programs towards marketing. Part of our ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Femoral neck fracture is the most common form of hip fracture with annual treatment costs in the U.S. estimated to be between $10 to $15 billion, and are expected to rise due to the aging population, with mortality rates of up to 36%. *click for further information about Muscle injury due to total hip ...
by:Science in Action based inNess Ziona, ISRAEL
SCOPUS is a Clinical Arm of “Science in Action” research organization that offers a broad range of clinical development services in all stages and aspects of study design. Our scientific background and “hands on” experience to design, develop and execute early as well as advanced clinical ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
A more seamless transition into the clinic. Complex biopharmaceuticals and advanced therapies can present challenges during preclinical development. When implementing an albumin-based solution, Albumedix can help avoid unnecessary complications in your preclinical testing by creating species-specific recombinant albumins to suit your preclinical models. ...
by:Science in Action based inNess Ziona, ISRAEL
We work according to current ICH-GCP requirements, all applicable local and global laws and ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Graft Versus Host Disease (GvHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells may identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
COVID-19 is caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause clusters of severe respiratory illness associated with the need for intensive care unit (ICU) admission and high mortality. Studies have shown that Acute Respiratory Distress Syndrome (ARDS) following viral pneumonia is one of the most common causes of death from ...